Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cingulate, Inc. (CING)
:CING
CING Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $20.83
Previous CloseN/A
Volume136.88K
Average Volume (3M)184.81K
Market Cap
$13.88M
Enterprise Value-$903.51K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta5.32
Next Earnings
Mar 07, 2025EPS Estimate
-1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-85.79
Shares Outstanding3,212,233
10 Day Avg. Volume96,964
30 Day Avg. Volume184,814
Standard Deviation0.34
R-Squared0.02
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.55
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$13.33Price Target Upside208.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cingulate Inc News
PremiumCompany Announcements
Cingulate Inc Completes Key FDA Study for ADHD Drug
PremiumCompany Announcements
Cingulate Inc Secures $5M Financing for Strategic Growth
---
Bulls Say, Bears Say
Bulls Say
FDA Approval ProcessCingulate has completed its final FDA-required clinical program for CTx-1301, which is a significant step towards FDA approval for the treatment of ADHD.
Market PotentialThe U.S. ADHD market is substantial, sized at approximately $23 billion, with Cingulate aiming to capture a significant portion through CTx-1301.
Bears Say
Risks And SetbacksRisks for Cingulate include commercial setbacks in ADHD, competition, financing, equity dilution, and regulatory setbacks.
---
Ownership Overview
63.15% Insiders
0.25% Mutual Funds
0.16% Other Institutional Investors
36.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate, Inc.’s price range in the past 12 months?
Cingulate, Inc. lowest stock price was $1.80 and its highest was $20.83 in the past 12 months.
What is Cingulate, Inc.’s market cap?
Cingulate, Inc.’s market cap is $13.88M.
When is Cingulate, Inc.’s upcoming earnings report date?
Cingulate, Inc.’s upcoming earnings report date is Mar 07, 2025 which is in 15 days.
How were Cingulate, Inc.’s earnings last quarter?
Cingulate, Inc. released its earnings results on Nov 07, 2024. The company reported -$1.83 earnings per share for the quarter, beating the consensus estimate of -$2.363 by $0.533.
Is Cingulate, Inc. overvalued?
According to Wall Street analysts Cingulate, Inc.’s price is currently Undervalued.
Does Cingulate, Inc. pay dividends?
Cingulate, Inc. does not currently pay dividends.
What is Cingulate, Inc.’s EPS estimate?
Cingulate, Inc.’s EPS estimate is -1.38.
How many shares outstanding does Cingulate, Inc. have?
Cingulate, Inc. has 3,212,233 shares outstanding.
What happened to Cingulate, Inc.’s price movement after its last earnings report?
Cingulate, Inc. reported an EPS of -$1.83 in its last earnings report, beating expectations of -$2.363. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Cingulate, Inc.?
Among the largest hedge funds holding Cingulate, Inc.’s share is GoalVest Advisory LLC. It holds Cingulate, Inc.’s shares valued at 0.
---
Company Description
Cingulate, Inc.
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
---
CING Stock 12 Month Forecast
Average Price Target
$13.33
▲(208.56% Upside)
Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-61.69%
reiterated a buy rating last month
Copying Naz Rahman's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -61.69% per trade.
---